The performance forecasts described in this material are rational based on the information currently available and have been determined by the Company as reasonable.
Considerable financial investment and a long development time are required before a new drug is launched. The Company carefully develop new drugs by confirming their efficacy and safety. There is a possibility that their development may be discontinued before completion, in such case where anticipated efficacy has not been proven or safety issues have been identified.
The "Products under Development" is based on the current development plans.
The status may change depending on their progress.
The information about pharmaceutical products (including those under development) included in this material is not intended as an advertisement or medical advice.
Reason for decline in net sales ・impact from NHI drug price revision and competitive products.
Reason for decline in profit
・increase in SG&A expenses, mainly from increase in R&D expenses.
(approx. ¥6,500 million, upfront fee of two in-licensed development products and experiment costs.)
・impairment loss on intangible
asset from discontinuation of
development of ART-648 for the planned indication of
bullous pemphigoids by
ARTham Therapeutics Inc. (approx. ¥1,500 million)
3
Consolidated Net Sales by Segment
(amounts are rounded down to the nearest million yen)
Kaken Pharmaceutical Co. Ltd. published this content on 11 May 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 May 2023 04:53:06 UTC.
KAKEN PHARMACEUTICAL CO., LTD. is a Japan-based company engaged in the production and sale of pharmaceutical products. The Company operates in two business segments. The Pharmaceutical segment involves in the manufacture and sale of pharmaceuticals, medical devices and agricultural drugs. The Real Estate segment is engaged in the leasing of real estate.
KAKEN PHARMACEUTICAL CO., LTD. 
